Genetic basis of intramedullary spinal cord tumors and therapeutic implications

Journal of Neuro-Oncology

Volumn 47, Issue 3, 2000, Pages 239-251

  Parsa, A T ^a   Fiore, A J ^a   McCormick, P C ^a   Bruce, J N ^a  

^a NEUROLOGICAL INSTITUTE   (United States)

Author keywords

Ependymoma; Gene therapy; Glioma; Spinal cord tumor

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; PLASMID VECTOR; VIRUS VECTOR;

ASTROCYTOMA; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DELIVERY SYSTEM; EPENDYMOMA; FAMILIAL DISEASE; GENE MUTATION; GENE THERAPY; GENETIC ANALYSIS; GENETIC ASSOCIATION; HEMANGIOBLASTOMA; HUMAN; MOLECULAR BIOLOGY; NEURILEMOMA; NEUROFIBROMATOSIS; NONHUMAN; REVIEW; SPINAL CORD TUMOR; VON HIPPEL LINDAU DISEASE;

EPENDYMOMA; GENE THERAPY; GENES, TUMOR SUPPRESSOR; GLIOMA; HUMANS; MUTATION; SPINAL CORD NEOPLASMS;

EID: 0033832314     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006422607122     Document Type: Review

References (131)

1. Charles Albert Elsberg 1871-1948
2. Artificial transmutation of the gene
3. Genetic effects of X-rays in maze
4. The molecular structure of nucleic acids: A structure for deoxyribose nucleic acid
5. The biochemistry of transcription in eukaryotes: A paradigm for multisubunit regulatory complexes
6. The concept of the gene: Short history and present status
7. Evolution of the intron-exon structure of eukaryotic genes
8. Mechanisms of pre-mRNA splicing: Classical versus non-classical pathways
9. Regulation of translation in eukaryotic systems
10. mRNA stability and the control of gene expression
11. Control of messenger RNA stability in higher eukaryotes
12. RNA fingerprinting and differential display using arbitrarily primed PCR
13. Direct cloning of differential display products eluted from northern blots
14. A rapid protocol for the authentication of isolated differential display RT-PCR CDNAs
15. Principles of differential display
16. Identification of fragments of human transcripts from a defined chromosomal region: Representational difference analysis of somatic cell hybrids
17. Genetically directed representational difference analysis-based positional cloning and snorthern analysis of candidate genes
18. Technology for microarray analysis of gene expression
19. DNA chips: Promising toys have become powerful tools
20. Gene chips and arrays revealed: A primer on their power and their uses
21. Fidelity of DNA polymerases for PCR
22. Neurofibromatosis. Clinical overview
23. Neurofibromatosis
24. Neurofibromatosis type 2 and von Hippel-Lindau disease: From gene cloning to function
25. Merlin: The neurofibromatosis 2 tumor suppressor
26. Intramedullary spinal cord tumors in neurofibromatosis
27. Intramedullary spinal cord tumour associated with neurofibromatosis type 1
28. Adult intramedullary astrocytomas of the spinal cord
29. Phenotypic variability in monozygotic twins with neurofibromatosis 2
30. A clinical variant of neurofibromatosis type 1: Familial spinal neurofibromatosis with a frameshift mutation in the NF1 gene
31. A point mutation associated with a severe phenotype of neurofibromatosis 2
32. Phenotypic variability associated with 14 splice-site mutations in the NF2 gene
33. A missense mutation in the NF2 gene results in moderate and mild clinical phenotypes of neurofibromatosis type 2
34. A genetic study of type 2 neurofibromatosis in the United Kingdom. II. Guidelines for genetic counselling
35. A mutation in the neurofibromatosis type 2 tumor-suppressor gene, giving rise to widely different clinical phenotypes in two unrelated individuals
36. Detection of a germline mutation and somatic homozygous loss of the von Hippel-Lindau tumor-suppressor gene in a family with a de novo mutation. A combined genetic study, including cytogenetics, PCR/SSCP, FISH, and CGH
37. Mutations in the VHL tumor suppressor gene and associated lesions in families with von Hippel-Lindau disease from central Europe
38. Haemangioblastoma of the central nervous system in von Hippel-Lindau disease. French VHL Study Group
39. Von Hippel-Lindau syndrome
40. Von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease
41. Somatic mutations of the von Hippel-Lindau tumor suppressor gene in sporadic central nervous system hemangioblastomas
42. Mutation of the von Hippel-Lindau tumour suppressor gene in capillary haemangioblastomas of the central nervous system
43. The von Hippel-Lindau tumor suppressor gene. A rare and intriguing disease opening new insight into basic mechanisms of carcinogenesis
44. Germline mutation profile of the VHL gene in von Hippel-Lindau disease and in sporadic hemangioblastoma
45. Somatic inactivation of the VHL gene in von Hippel-Lindau disease tumors
46. Structure of the VHL-ElonginC-ElonginB complex: Implications for VHL tumor suppressor function
47. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene
48. Significance of MIB-1, PCNA indices, and p53 protein over-expression in intramedullary tumors of the spinal cord
49. TP53 gene mutations and 17p deletions in human astrocytomas
50. p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma
51. Comparative study of p53 gene and protein alterations in human astrocytic tumors
52. Analysis of the neurofibromatosis 2 gene in human ependymomas and astrocytomas
53. Molecular pathways in the formation of gliomas
54. PTEN/MMACI mutations and EGFR amplification in glioblastomas
55. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers
56. PTEN/MMAC1 mutations in primary glioblastomas and short-term cultures of malignant gliomas
57. Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q
58. PTEN mutations in gliomas and glioneuronal tumors
59. Phosphatases and tumorigenesis
60. Intramedullary tumors in adults
61. Intramedullary ependymoma of the spinal cord
62. Frequent type 2, neurofibromatosis gene transcript mutations in sporadic intramedullary spinal cord ependymomas
63. Molecular genetic analysis of chromosome arm 17p and chromosome arm 22q DNA sequences in sporadic pediatric ependymomas
64. Molecular genetic analysis of ependymal tumors: NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas
65. Central neurocytomas of the cervical spinal cord. Report of two cases
66. Intramedullary spinal cord germinoma: Case report
67. Intramedullary spinal cord germinoma
68. Primary germinoma of the spinal cord: A case report with 28-year follow-up and review of the literature
69. Intramedullary spinal cord germinoma: Case report and review of the literature
70. Intramedullary non-Hodgkin's lymphoma of the spinal cord: A case report and literature review
71. Primary intramedullary lymphoma of the spinal cord mimicking cervical spondylotic myelopathy
72. Primary intramedullary primitive neuroectodermal tumor of the spinal cord: Case report and review of the literature
73. Intramedullary subependymoma of the spinal cord
74. Intramedullary neuroma of the cervical spinal cord: Case report
75. Intramedullary spinal teratoma and diastematomyelia. Case report and review of the literature
76. Intramedullary spinal cord lipomas
77. Retroviral vectors
78. Retroviruses as vectors
79. Retroviruses
80. Herpes virus-based vectors
81. Herpes simplex virus vectors for gene transfer to the nervous system
82. Targeting gene therapy vectors to CNS malignancies
83. CNS tumor therapy by attenuated herpes simplex viruses
84. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas
85. Adenoviral vectors for gene transfer
86. Adenovirus and adenoassociated virus mediated gene transfer
87. Gene therapy for neurologic disease: Benchtop discoveries to bedside applications. 2. The bedside
88. Non-viral approaches to gene therapy
89. In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment
90. Structural and functional analysis of cationic transfection lipids: The hydrophobic domain
91. Increased efficiency of liposome-mediated transfection by volume reduction and centrifugation
92. Activation of target-tissue immune-recognition molecules by double-stranded polynucleotides
93. Gene therapy for brain tumors
94. Cellular and molecular neurosurgery: Pathways from concept to reality - part II: Vector systems and delivery methodologies for gene therapy of the central nervous system
95. Cellular and molecular neurosurgery: Pathways from concept to reality - Part I: Target disorders and concept approaches to gene therapy of the central nervous system
96. Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line
97. Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene
98. Gene therapy of malignant brain tumors: A rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells
99. Toxicity studies of retroviral-mediated gene transfer for the treatment of brain tumors
100. Human malignant brain tumor response to herpes simplex thymidine kinase (HSVtk)/ganciclovir gene therapy
101. Adenovirus-mediated gene therapy for experimental spinal cord tumors: Tumoricidal efficacy and functional outcome
102. Bystander tumoricidal effect in the treatment of experimental brain tumors
103. The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats
104. Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo
105. A more potent bystander cytocidal effect elicited by tumor cells expressing the herpes simplex virus thymidine kinase gene than by fibroblast virus-producer cells in vitro
106. Regression of experimental brain tumors with 6-thioxanthine and Escherichia coli gpt gene therapy
107. Transduction of cytosine deaminase gene makes rat glioma cells highly sensitive to 5-flourocytosine
108. New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol (In Process Citation)
109. Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo
110. New approaches in brain tumor therapy using gene transfer and antisense oligonucleotides
111. Antisense oligonucleotides as therapeutic agents
112. Antisense oligonucleotides for central nervous system tumors
113. Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity
114. Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo
115. Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy
116. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence
117. Antisense strategies in neurobiology
118. Contribution of sequence and phosphorothioate content to inhibition of cell growth and adhesion caused by c-myc antisense oligomers
119. Lack of expression of tumor-suppressor genes in human malignant glioma cell lines
120. Timing of p53 mutations during astrocytoma tumorigenesis
121. The p53 gene and its role in human brain tumors
122. Intracavitary liposome-mediated p53 gene transfer into glioblastoma with endogenous wild-type p53 in vivo results in tumor suppression and long-term survival
123. Induction of differentiation by wild-type p53 gene in a human glioma cell line
124. Analysis of p53 gene mutations in low- and high-grade astrocytomas by polymerase chain reaction-assisted single-strand conformation polymorphism and immunohistochemistry
125. Adenovirus-mediated p53 gene transfer suppresses growth of human glioblastoma cells in vitro and in vivo
126. Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain
127. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN
128. Suppression of tumorigenicity of glioblastoma cells by adenovirus-mediated MMAC1/PTEN gene transfer
129. PTEN gene mutations are seen in high-grade but not in low-grade gliomas
130. Somatic mutations of PTEN in glioblastoma multiforme